Author:
Horber F,Egger H J,Weidekamm E,Dubach U C,Frey F J,Probst P J,Stoeckel K
Abstract
The pharmacokinetics of carumonam after a single 1,000-mg intravenous infusion (20 min) were evaluated in four groups of subjects who had various degrees of renal impairment: group 1, CLCR greater than 60 ml/min; group 2, CLCR = 30 to 60 ml/min; group 3, CLCR = 10 to 30 ml/min; and group 4, CLCR less than 10 ml/min). The elimination half-life of carumonam increased with decreasing creatinine clearance (CLCR) from 1.7 h in group 1 to 11.3 h in group 4. Peak carumonam concentration (103 micrograms/ml) and steady-state volume of distribution (12.8 liters) did not change with decreasing CLCR. Total body clearance (r = 0.98), renal clearance (r = 0.98), and nonrenal clearance (r = 0.67) of carumonam correlated with decreasing CLCR. Mean nonrenal clearance was 21 ml/min in group 1 and 12 ml/min in group 4. With regard to dosage, patients with a CLCR above 60 ml/min should receive their standard maintenance dose of carumonam without any changes; patients with a CLCR between 30 and 60 ml/min should receive the dose every 12 h; and individuals with a CLCR between 10 and 30 ml/min should be given the dose once a day. Patients with a CLCR of less than 10 ml/min should receive one-half of the dose once a day. Our recommended dosage regimens should produce within the CLCR borderlines of each group average plasma concentrations that are between one and two times that achieved in normal subjects with a t.i.d. dosage regimen.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference20 articles.
1. Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency;Bolton W. K.;Antimicrob. Agents Chemother.,1981
2. Brater D. C. and P. Chennavasin. 1984. Effects of renal disease: pharmacokinetic considerations p. 119-147. In L. Z. Benet et al. (ed.) Pharmacokinetic basis for drug treatment. Raven Press New York.
3. Prediction of creatinine clearance from serum creatinine;Cockroft D. W.;Nephron,1976
4. Drug dosage in renal disease;Dettli L.;Clin. Pharmacol.,1976
5. Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function;Drayer D. E.;Clin. Pharmacol. Ther.,1978
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献